Intuitive Surgical, Inc. (NASDAQ:ISRG) Insider Mark Brosius Sells 2,115 Shares

Intuitive Surgical, Inc. (NASDAQ:ISRG) insider Mark Brosius sold 2,115 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total value of $1,040,389.65. Following the transaction, the insider now owns 295 shares in the company, valued at $145,113.45. The sale was disclosed in a document filed with the SEC, which is available at this link.

Intuitive Surgical Trading Up 0.3 %

Intuitive Surgical stock opened at $491.39 on Tuesday. The business’s fifty day simple moving average is $464.67 and its two-hundred day simple moving average is $422.79. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $496.18. The company has a market capitalization of $174.30 billion, a price-to-earnings ratio of 88.70, a price-to-earnings-growth ratio of 5.41 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. The business had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.18 earnings per share. On average, equities research analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Creekmur Asset Management LLC lifted its holdings in shares of Intuitive Surgical by 200.0% during the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 42 shares in the last quarter. Ridgewood Investments LLC bought a new position in Intuitive Surgical in the second quarter valued at about $26,000. Able Wealth Management LLC bought a new position in Intuitive Surgical in the fourth quarter valued at about $28,000. Delos Wealth Advisors LLC lifted its holdings in Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 57 shares during the period. Finally, LRI Investments LLC bought a new position in Intuitive Surgical in the first quarter valued at about $30,000. 83.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on ISRG. Citigroup raised their target price on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Barclays raised their target price on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research report on Thursday, July 18th. Redburn Atlantic raised Intuitive Surgical from a “neutral” rating to a “buy” rating and raised their target price for the company from $380.00 to $510.00 in a research report on Friday, August 2nd. Robert W. Baird lifted their price objective on Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a report on Friday, July 19th. Finally, Piper Sandler lifted their price objective on Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $446.45.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.